VIENNA, Austria, March 6th, 2023 — Delta4, a digital drug discovery company focusing on the identification of new indications for […]
Author: Kurt Herpel
Delta4 joins the EU-funded COST action PerMediK (Personalized medicine in chronic kidney disease: improved outcome based on Big Data)
The scientific aim of PerMediK is to support the development of a path towards personalized medicine in chronic kidney disease […]
4P-Pharma And Delta4 Join Forces To Find And Develop Treatments For A Rare Autoimmune Chronic Liver Disease
Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical-stage biotechnology company, and Delta4, an Austrian digital […]
Delta4, in preparation for the first clinical study, focused on FSGS
Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological, and […]
Delta4 at BIO-EUROPE 2021
From October 25-28 Delta4 attended the (virtual) BIO-EUROPE conference, the largest partnering event in Europe dedicated to the global biotechnology […]
Delta4 Announces Dr. Hans Lehrach to Join Scientific Advisory Board
VIENNA, Austria, September 27th, 2021 — Delta4, a digital drug discovery company focusing on the identification of new indications for […]
FSGS and COVID-19 programs ready for Phase II studies
We are proud to announce further progress in our current drug discovery and development programs. In late 2020, Delta4 filed […]
Delta4 files four patent applications in FSGS and COVID-19
We are very pleased to announce that Delta4 has filed four patent applications for compounds and combinations of compounds in […]
Sachs 20th Annual Biotech In Europe Forum
The 20th Annual Biotech in Europe (BEF) Forum is recognized as the leading international Stage for those interested in investing […]
World Orphan Drug Congress
With over 1,500 attendees from 50+ countries, the 2020 edition of the World Orphan Drug Congress USA was held online […]